Page 148 WHO - Guidelines on the pharmacological treatment of persisting pain in children with medical illness

US$ 1500 from Neuromed in 2008; US$ 2000 from Anesiva and US$ 1000 from Endo in 2007; and
US$ 2500 from Cephalon in 2006.
A1
Boris Zernikow reported having received payments for consultancies from pharmaceutical companies of:
approximately Euro 2000 from Reckitt Benckiser in 2007; Euro 2000 from Janssen in 2008; Euro 1500
from Wyeth in 2008; approximately Euro 20 000 from Grunenthal since 2008; and around Euro 1000
from Schwarz Pharma. He declared having received lecturer fees from several pharmaceutical companies
since 2006 for a total of around Euro 16 000. He also declared having received congress sponsoring
from several companies in 2007, 2009 and 2010, for a total of around Euro 116 000, and research
support from several foundations.
A2
The other external reviewers reported no conflicts of interest.

Management of potential conflicts of interest of the external reviewers

The comments provided by Rosa Buitrago, Stuart MacLeod, Gary Walco and Boris Zernikow related to
improvement of the text and did not conflict with any recommendation and/or principle issued by the
Guidelines Development Group. A3

A4

A5

A6

A7

145 <